Loxiglumide 10 mg | Purity Not Available
TargetMol
Loxiglumide
Search Results
BIIB021 5 mg | 98.38%
TargetMol
BIIB021 is an orally-available, fully synthetic inhibitor of HSP90(Ki=1.7 nM, EC50=38 nM).
More Information Supplier PageBIIB021
BIIB021 50 mg | 98.38%
TargetMol
BIIB021 is an orally-available, fully synthetic inhibitor of HSP90(Ki=1.7 nM, EC50=38 nM).
More Information Supplier PageBIIB021
BIIB021 200 mg | 98.38%
TargetMol
BIIB021 is an orally-available, fully synthetic inhibitor of HSP90(Ki=1.7 nM, EC50=38 nM).
More Information Supplier PageBIIB021
Tolvaptan 5 mg | 97.00%
TargetMol
Tolvaptan is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
More Information Supplier PageTolvaptan
Enasidenib 100 mg | Purity Not Available
TargetMol
Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity.
More Information Supplier PageEnasidenib
Enasidenib 10 mg | Purity Not Available
TargetMol
Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity.
More Information Supplier PageEnasidenib
Fasiglifam 5 mg | Purity Not Available
TargetMol
Fasiglifam (TAK875) is a potent, selective and orally bioavailable GPR40 agonist.
More Information Supplier PageFasiglifam
Fasiglifam 50 mg | Purity Not Available
TargetMol
Fasiglifam (TAK875) is a potent, selective and orally bioavailable GPR40 agonist.
More Information Supplier PageFasiglifam
Fasiglifam 10 mg | Purity Not Available
TargetMol
Fasiglifam (TAK875) is a potent, selective and orally bioavailable GPR40 agonist.
More Information Supplier PageFasiglifam